RBP-6300 is an oral tablet combining buprenorphine hemiadipate hydrochloride and naloxone hydrochloride. It is studied in opioid-related disorders, with participants taking 10, 20 or 30 mg/day during a transfer period.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.